Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Marie Skłodowska-Curie Action · Running

EDIOM Elucidating drivers of human Inflammatory Bowel Disease by next-generation organoid modeling

Coordinator
Academisch Ziekenhuis Leiden, Netherlands
Runs
1 November 2023 to 31 October 2025
Status
Running
EU funding
€188k
Total cost
—
Partners
2 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101109788

What the project is doing

In the project's own words, from its summary on CORDIS.

Inflammatory Bowel Disease (IBD) is a collective term for bowel diseases caused by undesired immune reactions and can currently not be cured. To develop adequate treatments for IBD, we need to understand the nature and cause(s) of the pathogenic immune responses observed. To identify mechanisms driving IBD in humans, we need apart from diagnostic correlative studies, adequate in vitro cell models that realistically recapitulate the in vivo situation and allow for intervention studies.

Thus far, in vitro models that incorporate next to intestinal epithelium also supportive stroma and immune cells are lacking. In my PhD studies, I generated a map of the IBD-associated immune cell network by single-cell analyses of healthy and IBD patient samples. In my postdoctoral work, I have developed an Air Liquid Interphase (ALI) intestinal organoid platform derived from human samples that supports tissue-resident immune cells.

In this project, I aim to identify cellular and molecular networks driving IBD by diagnostic and intervention studies in intestinal ALI organoids. For this purpose, I will: 1) Validate ALI intestinal organoids as accurate ex vivo model by analyzing their immune cell composition and functionality in spatial context; and 2) aligning this with the in vivo situation by data mining of public single-cell RNA-seq of inflamed intestines. 3) Integrate datasets generated in 1-2) to reveal cellular and molecular immune cell interactions associated with IBD; and 4) Implicate interactions identified under 3) in driving IBD by molecularly targeted interventions in ALI organoids.

The proposed work will take place at host institute Leiden Univ. Medical Center, with a 4-month secondment phase at Technical Univ. Delft. This project is expected to deliver insight into immunological mechanisms driving IBD and clinically translatable therapeutic interventions, by mechanistic studies in a novel in vitro system mimicking the in vivo cellular environment of human IBDs.

Who is involved

OrganisationCityCountryRole
Academisch Ziekenhuis LeidenLeidenNetherlandsCoordinator
Technische Universiteit DelftDelftNetherlandsAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI